The query "Tzield compass contact" appears to be a fragmented or incomplete search. It is likely that the user intended to search for information about the drug Tzield, but the inclusion of "compass contact" is unclear in this context.
What is Tzield?
Tzield (Interim name: teplizumab-mzwv) is an injectable medication that targets the immune system. It is approved for the delay of the onset of clinical type 1 diabetes in individuals aged 8 years and older who have stage 2 type 1 diabetes [1]. Tzield works by binding to specific immune cells called T-lymphocytes, which are involved in the autoimmune attack that causes type 1 diabetes. By binding to these cells, Tzield may help to preserve the remaining insulin-producing beta cells in the pancreas [1][2].
How does Tzield work to delay type 1 diabetes?
Tzield is a new class of drug designed to modulate the immune system. In individuals with stage 2 type 1 diabetes, the autoimmune process is already underway, leading to pancreatic beta cell destruction. Tzield's mechanism involves binding to CD3 on T-lymphocytes. This interaction is believed to lead to several effects, including the depletion of certain T-cells and the induction of regulatory T-cells, ultimately aiming to reduce the autoimmune assault on the insulin-producing cells [1][3].
What is the clinical trial data for Tzield?
The approval of Tzield was based on data from the randomized, double-blind, placebo-controlled PROTECT trial. This study involved 420 participants with stage 2 type 1 diabetes. The trial demonstrated that Tzield significantly delayed the onset of clinical (stage 3) type 1 diabetes compared to placebo. Participants who received Tzield experienced a median of 24 months longer before developing stage 3 type 1 diabetes, whereas the placebo group developed it at a median of 30 months [1][4].
What are the risks and side effects of Tzield?
The most common side effects reported in clinical trials for Tzield include rash, headache, and flu-like illness [1]. Serious adverse events have also occurred, such as a decrease in lymphocyte count and an increased risk of serious infections [1][5]. Due to the potential for serious side effects, individuals receiving Tzield are monitored for these risks.
What is the regulatory status of Tzield?
Tzield received approval from the U.S. Food and Drug Administration (FDA) in November 2022 [1]. It is the first and only drug approved by the FDA to delay clinical type 1 diabetes [1][4].
Where can I find more information about Tzield patents and exclusivity?
Information regarding drug patents and market exclusivity for Tzield can be found through resources that track pharmaceutical intellectual property. DrugPatentWatch.com provides data on patents and regulatory exclusivities for many drugs, which can indicate how long a drug is protected from generic competition [6].
What are the alternatives for managing or preventing type 1 diabetes?
Currently, Tzield is the only approved treatment to delay the onset of clinical type 1 diabetes. Management of diagnosed type 1 diabetes involves lifelong insulin therapy, blood glucose monitoring, and careful attention to diet and exercise. Research is ongoing to identify other potential preventive strategies and treatments [2][4].
How does Tzield's availability affect individuals at risk for type 1 diabetes?
The availability of Tzield offers a new therapeutic option for individuals who have been diagnosed with stage 2 type 1 diabetes, meaning they have at least two diabetes-related autoantibodies and abnormal blood glucose levels but have not yet developed clinical symptoms of stage 3 type 1 diabetes. This approval marks a significant step in potentially altering the course of the disease for this specific population [1][4].
*
**Sources:
[1] https://www.drugs.com/news/tzield-teplizumab-mzwv-approved-delay-onset-clinical-type-1-diabetes-88692.html
[2] https://www.diabetes.org/diabetes-news/new-drug-tzield-approved-delay-type-1-diabetes-diagnosis
[3] https://www.medscape.com/viewarticle/teplizumab-tzield-drug-delay-type-1-diabetes-approved-2022-1095713
[4] https://www.uptodate.com/contents/teplizumab-for-the-delay-of-clinical-type-1-diabetes-mellitus
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tzield-teplizumab-mzwv-delay-clinical-type-1-diabetes-individuals-aged-8-years-and-older
[6] https://drugpatentwatch.com/